Inflammagen's Shok-Pak Taking on Septic Stock in Phase II Trial
If early human trial results from Inflammagen Therapeutics Inc. are borne out in its new Phase II pilot study, disclosed Monday, the company could have a major blockbuster on its hands, according to CEO John Rodenrys.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter